{
"id":"mk19_b_en_f02",
"number":2,
"bookId":"en",
"legend":{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Pharmacologic treatment for patients with type 2 diabetes mellitus. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; DPP-4i = dipeptidyl peptidase-4 inhibitor; GLP-1 RA = glucagon-like peptide 1 receptor agonist; HF = heart failure; SGLT2i = sodium-glucose cotransporter 2 inhibitor; SFU = sulfonylurea; TZD = thiazolidinedione."
]
},
"footnotes":[
[
"Data from American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S111-S124. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298420",
"target":"_blank"
},
"children":[
"PMID: 33298420"
]
},
" doi:10.2337/dc21-S009"
]
],
"imageInfo":{
"hash":"607cb03e6443fb017280d73170beb3ab",
"height":340,
"width":609,
"extension":"svg",
"vector":true
}
}